CCMH
CLDX icon

Cornerstone Capital Management Holdings’s Celldex Therapeutics CLDX Stock Holding History

Cornerstone Capital Management Holdings’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-7,054
Closed -$261K – 1275
2017
Q2 		$261K Buy
7,054
+375
+6% +$16.6K ﹤0.01% 1122
2017
Q1 		$361K Buy
+6,679
New +$348K ﹤0.01% 1099
2016
Q1 		– Sell
-441
Closed -$104K – 1499
2015
Q4 		$104K Buy
441
+114
+35% +$24.9K ﹤0.01% 1306
2015
Q3 		$52K Sell
327
-346
-51% -$97.9K ﹤0.01% 1399
2015
Q2 		$255K Buy
673
+6
+0.9% +$2.38K ﹤0.01% 1154
2015
Q1 		$279K Buy
667
+200
+43% +$71.5K ﹤0.01% 1121
2014
Q4 		$128K Buy
467
+154
+49% +$38.3K ﹤0.01% 1136
2014
Q3 		$61K Sell
313
-214
-41% -$46.6K ﹤0.01% 1206
2014
Q2 		$128K Buy
+527
New +$119K ﹤0.01% 1160

Other funds holding CLDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KE
KLP Enterprises Branford, Connecticut $1.97M AUM
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Cornerstone Capital Management Holdings's CLDX Position: Q3 2017 in Review

Cornerstone Capital Management Holdings sold out of Celldex Therapeutics (CLDX) in Q3 2017, closing a stake of 7,054 shares — an estimated $261K sold.

Cornerstone Capital Management Holdings first reported a position in CLDX in Q2 2014 and held it in 9 quarters. The position peaked at $361K in Q1 2017. 129 funds tracked by Wall St. Rank hold CLDX as of Q3 2017.

  • Cornerstone Capital Management Holdings reported no remaining Celldex Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Cornerstone Capital Management Holdings sold 7,054 Celldex Therapeutics shares in Q3 2017, an estimated $261K.
  • Cornerstone Capital Management Holdings first reported a position in Celldex Therapeutics in Q2 2014 and held it in 9 quarters.
  • Cornerstone Capital Management Holdings's Celldex Therapeutics position peaked at $361K in Q1 2017.
  • 129 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2017.

Based on Cornerstone Capital Management Holdings's 13F filing for Q3 2017, filed 14 Nov 2017.